46
46K.F IRadimed Corporation
- Market cap
- EUR 985M
- P/E
- 48.1x
- P/B
- 10.31x
- ROE
- 22.0%
- Dividend yield
- 0.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 46K.F undervalued?
Graham numberThe Graham number of IRadimed Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IRadimed Corporation fundamental analysis
No fundamental analysis for IRadimed Corporation yet.
IRadimed Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detect…
Full company profileIRadimed Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IRadimed Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.5M | 23.1M | 30.4M | 38.5M | 31.7M | 41.8M | 53.3M | 65.6M | 73.2M | 83.8M | 88.9M |
| Gross Profit | 26.3M | 17.5M | 23.2M | 29.7M | 23.6M | 32.0M | 41.3M | 50.2M | 56.4M | 64.3M | 67.2M |
| Operating Income | 10.9M | 1.29M | 6.00M | 8.65M | -756K | 9.82M | 15.6M | 20.0M | 22.0M | 26.1M | 29.0M |
| EBITDA | - | 2.59M | 7.11M | 9.89M | 583K | 11.2M | 16.3M | 20.8M | 22.8M | 27.3M | 30.7M |
| Net Income | 7.21M | 500K | 6.30M | 9.63M | 1.37M | 9.33M | 12.8M | 17.2M | 19.2M | 22.5M | 23.4M |
| EPS | - | 0.05 | 0.57 | 0.82 | 0.11 | 0.76 | 1.02 | 1.36 | 1.51 | 1.76 | 1.83 |
| Balance Sheet | |||||||||||
| Total Assets | 37.2M | 39.0M | 48.4M | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 98.3M | 109M | 121M |
| Total Liabilities | 5.31M | 6.08M | 6.50M | 11.2M | 9.68M | 10.7M | 11.8M | 20.7M | 11.5M | 14.2M | 14.6M |
| Shareholders' Equity | 31.9M | 32.9M | 41.9M | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 86.8M | 94.6M | 106M |
| Cash & Short-term Investments | 17.7M | 18.2M | 28.0M | 43.5M | 50.1M | 62.0M | 58.0M | 49.8M | 52.2M | 51.2M | 63.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.41M | 3.42M | 7.38M | 10.2M | 5.82M | 11.3M | 10.0M | 12.6M | 25.6M | 24.9M | 28.3M |
| Capital Expenditure | 1.52M | 776K | 228K | 368K | 443K | 482K | 823K | 7.85M | 8.82M | 8.42M | 1.50M |
| Free Cash Flow | - | 2.59M | 7.11M | 9.75M | 5.18M | 10.5M | 8.17M | 4.75M | 16.8M | 16.5M | 26.8M |
| Ratios | |||||||||||
| ROE | 22.6% | 1.5% | 15.0% | 17.3% | 2.2% | 12.9% | 17.4% | 24.1% | 22.2% | 23.8% | 22.0% |
| ROA | 19.4% | 1.3% | 13.0% | 14.4% | 1.9% | 11.3% | 15.0% | 18.7% | 19.6% | 20.7% | 19.3% |
| Net Profit Margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% | 26.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IRadimed Corporation dividends
- Dividend yield
- 0.93%
- Forward dividend
- 0.71 EUR
- Payout ratio
- 66.9%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 15.0M | 1.18 | 66.9% |
| 2024 | USD 13.7M | 1.08 | 71.1% |
| 2023 | USD 13.2M | 1.04 | 76.9% |
| 2022 | USD 12.6M | 1.00 | 97.9% |
| 2021 | USD 12.6M | 1.02 | 134.7% |
| 2020 | USD 12.6M | 1.02 | 917.4% |
| 2019 | USD 12.6M | 1.07 | 130.4% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns IRadimed Corporation
- Insiders 35.18%
- Institutions 63.45%
- Public & others 1.37%
- Shares outstanding 12.8M
- Free float 8.33M
IRadimed Corporation company profile
- Company name
- IRadimed Corporation
- Ticker
- 46K.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 166
- Fiscal year end
- December
- Address
- 12705 Ingenuity Drive, Orlando, FL, United States, 32826
- Phone
- 407 677-8022
- Website
- iradimed.com
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
IRadimed Corporation management
7- Mr. Roger E. SusiFounder, Chairman, CEO & President · born 1953
- Mr. John F. GlennCFO & Corporate Secretary · born 1962
- Mr. Jeff ChiprinChief Commercial Officer · born 1966
- Mr. Randy WaddellVice President of Worldwide Sales & Marketing
- Mr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information Technology
- Mr. Matt GarnerController
- Mr. Lynn NeuhardtVice President of Research & Development